TERT Gene Leukemia Genetic Test
Introduction
The TERT gene is responsible for encoding the telomerase reverse transcriptase enzyme, which plays a crucial role in maintaining the length of telomeres (protective caps at the ends of chromosomes) during cell division. Mutations in the TERT gene have been associated with various cancers, including leukemia.
Leukemia and Acute Myeloid Leukemia (AML)
Leukemia is a type of cancer that affects the blood and bone marrow, leading to the abnormal production of white blood cells. Acute myeloid leukemia (AML) is a specific subtype of leukemia that arises from abnormal myeloid cells in the bone marrow.
TERT Germline Mutation and AML Susceptibility
In some cases, individuals may inherit a germline mutation in the TERT gene, which means the mutation is present in all cells of the body and can be passed on to future generations. This germline mutation in TERT can increase the susceptibility to developing AML.
TERT Gene Leukemia Genetic Test
To determine the presence of a TERT germline mutation, a genetic test called next-generation sequencing (NGS) can be performed. NGS is a high-throughput sequencing technology that allows for the analysis of multiple genes simultaneously. It can identify specific mutations or variations in the TERT gene that may be associated with an increased risk of developing AML.
Test Details
- Test Name: TERT Gene Leukemia acute myeloid form susceptible due to TERT germline mutation Genetic Test
- Components: NGS Technology
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Test Type: Hematology
- Doctor: Hematologist
- Test Department: Genetics
- Pre Test Information: Clinical History of Patient who is going for TERT Gene Leukemia, acute myeloid form, susceptible due to TERT germline mutation NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with TERT Gene Leukemia, acute myeloid form, susceptible due to TERT germline mutation NGS Genetic DNA Test gene TERT
Benefits of the TERT Gene Leukemia Genetic Test
By identifying individuals with TERT germline mutations, healthcare providers can offer targeted screening, surveillance, and counseling for early detection and prevention of AML. Additionally, this information can be used to inform treatment decisions and potentially develop personalized therapies for individuals with TERT-related AML.
| Test Name | TERT Gene Leukemia acute myeloid form susceptible due to TERT germline mutation Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Hematology |
| Doctor | Hematologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for TERT Gene Leukemia, acute myeloid form, susceptible due to TERT germline mutation NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with TERT Gene Leukemia, acute myeloid form, susceptible due to TERT germline mutation NGS Genetic DNA Test gene TERT |
| Test Details |
The TERT gene is responsible for encoding the telomerase reverse transcriptase enzyme, which plays a crucial role in maintaining the length of telomeres (protective caps at the ends of chromosomes) during cell division. Mutations in the TERT gene have been associated with various cancers, including leukemia. Leukemia is a type of cancer that affects the blood and bone marrow, leading to the abnormal production of white blood cells. Acute myeloid leukemia (AML) is a specific subtype of leukemia that arises from abnormal myeloid cells in the bone marrow. In some cases, individuals may inherit a germline mutation in the TERT gene, which means the mutation is present in all cells of the body and can be passed on to future generations. This germline mutation in TERT can increase the susceptibility to developing AML. To determine the presence of a TERT germline mutation, a genetic test called next-generation sequencing (NGS) can be performed. NGS is a high-throughput sequencing technology that allows for the analysis of multiple genes simultaneously. It can identify specific mutations or variations in the TERT gene that may be associated with an increased risk of developing AML. By identifying individuals with TERT germline mutations, healthcare providers can offer targeted screening, surveillance, and counseling for early detection and prevention of AML. Additionally, this information can be used to inform treatment decisions and potentially develop personalized therapies for individuals with TERT-related AML. |
